Hero

chimera biotec GmbH

Main Industry
Research & Development
updated 
updated 
SaveShare

Key Facts

This company profile is a search result of implisense.com

E-Mail

info@chimera-biotec.com

Website

https://www.chimera-biotec.com/

Phone

+49 231 9742840

Industries

Research & Development (M72)

Products and Services

PlasmaPCRImmunoassays

Size (Revenue & Employees)

Small company

Balance sheet total

3 M €

Purpose

1) die Herstellung und der Vertrieb von Bindeprotein-Nukleinsäure-Konjugaten und deren Anwendungen im Bereich der Analytik
2) die Forschung und Entwicklung auf den in Absatz 1 genannten Gebieten

Legal Form

GmbH

Commercial Register

Bremen
HRB 38763 HB

Legal Entity Identifier (LEI)

391200F3FE7B89AM3T63

Incorporation

00.00.0000

Capital Stock

€ 111,111.11

Historical Names

—

Show more
More? Implisense Plus!

Order Implisense Plus now for full company profiles and complete functionality! You will then have access to our GDPR-compliant real-time contact search, full annual reports, all search filters, complete search results and integrated AI analyses of the business model and management report.

  • Real-time search for contact persons
  • Complete annual reports
  • More search filters and results
Order now

Customer Relationship Intelligence: The Key to Optimizing your Sales Processes

Use our AI-powered assistants to identify the right companies, track current developments and market changes, reach relevant decision-makers and perfect your sales strategy with data-based insights. All seamlessly integrated into your CRM.

  • Find the right companies
  • Keep an eye on your target companies
  • Reach the right decision-makers
  • Increase your closing rate

Learn more

Executive Summary

Implisense Assist gives you the opportunity to use AI to find out about companies via chat, analyze them and much more. We from the Implisense team also provide you with ready-made analyses, e.g., an executive summary and a financial analysis. Just try it out for yourself!

Implisense Plus
implisense assist

profile random user logo

implisense assist

Contacts

  • Dr. Christian Wietholt

Timeline

Register Announcements

chimera biotec GmbH: Eigenkapitalquote nimmt zu aber Rückstellungen nehmen 2023 nennenswert ab

Die Eigenkapitalquote der chimera biotec GmbH hat sich im Fiskaljahr 2023 um % gesteigert und die Rückstellungen um % auf Euro bedeutend gesenkt, was auf eine Abnahme der erwarteten zukünftigen Ausgaben hinweist. Der vor kurzem veröffentlichte Jahresabschluss kann jetzt eingesehen werden und enthält umfangreiche Kennzahlen und Analysen.
Annual Reports
Show report

chimera biotec GmbH 2022: Bemerkenswerte Zunahme bei Eigenkapital sowie Bilanzsumme!

Das Eigenkapital der chimera biotec GmbH hat sich um % im Vorjahresvergleich auf Euro sowie die Bilanzsumme um % auf Euro deutlich erhöht. Diese Veränderung liefert Hinweise auf eine Erhöhung der Vermögensbasis. Der vor kurzem veröffentlichte Jahresabschlussbericht für das Jahr 2022 steht ab sofort zur Verfügung und beinhaltet umfangreiche Ergebnisse und Perspektiven.
Annual Reports
Show report

Abschluss des Förderprojektes "Verbundprojekt: Der erste Breit-Spektrum Wirkstoff gegen die potenziell pandemischen Flaviviren Zika, Dengue und West Nil Virus, Teilprojekt: Analysemethoden zur Quantifizierung von flaviviralen Infektionen sowie zur Entwicklung von Wirkstoffkandidaten" (BMBF 01QE2001B)

Heute endet das Förderprojekt "Verbundprojekt: Der erste Breit-Spektrum Wirkstoff gegen die potenziell pandemischen Flaviviren Zika, Dengue und West Nil Virus, Teilprojekt: Analysemethoden zur Quantifizierung von flaviviralen Infektionen sowie zur Entwicklung von Wirkstoffkandidaten". Es wurde vom BMBF unter dem Förderkennzeichen 01QE2001B für die chimera biotec GmbH mit einer Summe von 245.968,00 Euro gefördert. Die Laufzeit des Projektes betrug 44 Monate.
Funding

Abschluss des Förderprojektes "Verbundprojekt: Entwicklung einer Technologie-Plattform für eine nadelfreie sublinguale Vakzinierungs- und Immunisierungsstrategie, Teilprojekt: Analyse der Immunaktivität und erfolgreichen Immunisierung gegen das Zielpeptid nach Anwendung der entwickelten nadelfreien Vakzinierungsstrategie" (BMBF 01QE1906B)

Heute endet das Förderprojekt "Verbundprojekt: Entwicklung einer Technologie-Plattform für eine nadelfreie sublinguale Vakzinierungs- und Immunisierungsstrategie, Teilprojekt: Analyse der Immunaktivität und erfolgreichen Immunisierung gegen das Zielpeptid nach Anwendung der entwickelten nadelfreien Vakzinierungsstrategie". Es wurde vom BMBF unter dem Förderkennzeichen 01QE1906B für die chimera biotec GmbH mit einer Summe von 199.910,00 Euro gefördert. Die Laufzeit des Projektes betrug 39 Monate.
Funding

Abschluss des Förderprojektes "KMU-innovativ-19: dINA - Digitale Immunoassays für hochsensitive Analysen mit breitem dynamischen Bereich" (BMBF 031B0404A)

Heute endet das Förderprojekt "KMU-innovativ-19: dINA - Digitale Immunoassays für hochsensitive Analysen mit breitem dynamischen Bereich". Es wurde vom BMBF unter dem Förderkennzeichen 031B0404A für die chimera biotec GmbH mit einer Summe von 469.008,00 Euro gefördert. Die Laufzeit des Projektes betrug 42 Monate.
Funding
Latest News

Search in real time for news and events – topic-specific, live, and contextual to the selected company.

Implisense Plus
Show entire timeline

Network

Discover connections between companies via managers, shareholdings, links or addresses here.

Register to see more connections via management and web links. Get access to an interactive network to better understand the environment of this company.

Show more

Products & Technologies

Plasma
PCR
Immunoassays
Cytokine
Vaccine
Tools
Peptide
Enzyme
Software
See all 20 entries

Register for a free Implisense account to get advanced analysis and more extensive search results.

Show more

chimera biotec GmbH is mentioned in public sources in the context of the following products and services. Plasma, PCR and Immunoassays are the most common. The ranking list shown is without guarantee of completeness or correctness.

CRMCRM-System
Microsoft ProductsMicrosoft Office

The following software solutions, technologies and concepts are often referenced in job postings and press releases of chimera biotec GmbH. Most frequently recognized were CRM-System and Microsoft Office.

Dominance, Competence, ClarityInnovation, Passion, CreativityHarmony, Reliability, CommunicatibilityDilligence, Introspection, Thoroughness

Dominance, Competence, Clarity

Innovation, Passion, Creativity

Harmony, Reliability, Communicatibility

Dilligence, Introspection, Thoroughness

The 4 Color Scheme separates people and their personalities into four groups. chimera biotec GmbH emphasizes the following character types in their external communications and job advertisements.

You can find more information on the FAQ page.

Information for Job Seekers

Based on job advertisements of chimera biotec GmbH, the following specific requirements for job seekers were identified more frequently. Specific requirements can be found in the latest published job advertisements.

Persönliche Kompetenz

  • Einsatzbereitschaft
  • Motivation

Soziale Kompetenz

  • Emotionale Intelligenz

The following additional requirements were identified more frequently. These may vary and are provided for guidance.

  • Reisebereitschaft
  • Sprachkenntnisse
Register for free and try Implisense Plus!

Register quickly and easily for a free Implisense account. Registered users have access to extended company profiles and receive more comprehensive search results. If you register with a business email address, we will also set up a free 7-day trial for Implisense Plus in a timely manner.

  • Richer Company Profiles
  • Expanded Search Results
  • Personal Favourites

Register now

The company information presented on implisense.com comes from public sources and is verified and aggregated automatically. Implisense cannot guarantee the timeliness, completeness, quality, reliability or accuracy of the data. For questions or suggestions, please use the contact form.

This website uses cookies to provide this service and improve the user experience. Please select the cookies you wish to accept. You can find further information in our data protection declaration.

Some cookies from this site are necessary for the functionality of this service or enhance the user experience. Since these cookies either do not contain any personal data (e.g. language preference) or are very short-lived (e.g. session ID), cookies from this group are mandatory and cannot be deactivated.
To improve our services, we use user statistics such as Google Analytics, which set cookies for user identification. Google Analytics is a service offered by a third party provider.
To improve our services we use proprietary marketing solutions from third parties. These solutions specifically include Google AdWords and Google Optimize, which each set one or more cookies.
Some cookies from this site are necessary for the functionality of this service or enhance the user experience. Since these cookies either do not contain any personal data (e.g. language preference) or are very short-lived (e.g. session ID), cookies from this group are mandatory and cannot be deactivated.Some cookies from this site are necessary for the functionality of this service or enhance the user experience. Since these cookies either do not contain any personal data (e.g. language preference) or are very short-lived (e.g. session ID), cookies from this group are mandatory and cannot be deactivated.
To improve our services, we use user statistics such as Google Analytics, which set cookies for user identification. Google Analytics is a service offered by a third party provider.Some cookies from this site are necessary for the functionality of this service or enhance the user experience. Since these cookies either do not contain any personal data (e.g. language preference) or are very short-lived (e.g. session ID), cookies from this group are mandatory and cannot be deactivated.
To improve our services we use proprietary marketing solutions from third parties. These solutions specifically include Google AdWords and Google Optimize, which each set one or more cookies.Some cookies from this site are necessary for the functionality of this service or enhance the user experience. Since these cookies either do not contain any personal data (e.g. language preference) or are very short-lived (e.g. session ID), cookies from this group are mandatory and cannot be deactivated.

Save selectionSelect all